FIAU WARNING LETTER MAY ENCOURAGE "OVER-REPORTING" OF ADVERSE EVENTS, LILLY
Executive Summary
FIAU WARNING LETTER MAY ENCOURAGE "OVER-REPORTING" OF ADVERSE EVENTS, LILLY alleges in its June 29 response to FDA's May 11 warning letter regarding the conduct of a Phase I/II study of the antiviral fialuridine. Responding to FDA's claim that Lilly did not promptly report adverse events seen in the study, Lilly maintained that "questioning Lilly's good faith judgments... would only encourage companies to over-report adverse events, which would serve no useful purpose."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth